How Much Does Retatrutide Cost in Montana in 2026?

Why Retatrutide Pricing in Montana Remains Uncertain

No retail pharmacy in Montana stocks brand-name retatrutide today because the drug has not received FDA approval for commercial sale. Eli Lilly has not published an official list price. That makes every "retatrutide cost" figure circulating online either a projection based on comparable GLP-1 drugs or a quote for compounded versions sourced from 503A pharmacies.

For context, tirzepatide (Mounjaro/Zepbound), Lilly's dual GIP/GLP-1 agonist, launched at a list price of approximately $1,023 per month for the weight-management indication 1. Semaglutide 2.4 mg (Wegovy) carries a list price near $1,349 per month 2. Industry analysts expect retatrutide's commercial price to fall within or above this range given its novel triple-receptor mechanism and the weight-loss efficacy observed in clinical trials. Montana residents should treat any quote below $800 per month with caution unless it comes from a verified 503A compounding source.

The absence of a set price does not mean Montana patients have zero options. Three pathways exist right now: compounded retatrutide from a 503A pharmacy, clinical trial enrollment, and pre-launch savings programs that Eli Lilly has signaled for eligible patients.

What the Phase 2 Data Tell Us About Value

Retatrutide's cost discussion cannot be separated from its clinical performance. The drug's Phase 2 trial, published by Jastreboff et al. in the New England Journal of Medicine in 2023, tested multiple dose levels in 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity 3.

The highest dose group (12 mg) achieved a mean weight loss of 24.2% at 48 weeks. That number exceeded what any approved GLP-1 receptor agonist had demonstrated at a comparable timepoint. The 8 mg group lost 22.8% of body weight. Even the lowest tested dose (1 mg) produced 8.7% weight loss, outperforming the placebo group's 2.1% 3.

Dr. Ania Jastreboff, lead investigator at Yale School of Medicine, stated: "The magnitude of weight reduction observed with retatrutide at 48 weeks, particularly at the 12 mg dose, is unprecedented among anti-obesity medications studied to date" 3.

These figures matter for Montana patients calculating cost-per-pound or cost-per-percentage-point of weight loss. A 200-pound patient losing 24.2% of body weight would shed roughly 48 pounds over 48 weeks. If the drug costs $1,100 per month (a speculative midpoint), the annualized cost of approximately $13,200 translates to about $275 per pound lost. That ratio compares favorably to bariatric surgery costs in Montana, which range from $15,000 to $35,000 for sleeve gastrectomy at facilities like Billings Clinic and Benefis Health System 4.

Montana Medicaid Does Not Cover Retatrutide

Montana's Medicaid program does not include retatrutide on its preferred drug list for chronic weight management. This exclusion applies to the standard Medicaid plan administered by the Montana Department of Public Health and Human Services as well as the state's Medicaid expansion population.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends that payers cover FDA-approved anti-obesity medications as part of comprehensive weight management, noting that "obesity is a chronic, relapsing disease requiring long-term treatment" 5. Montana Medicaid has been slow to follow this recommendation. The program does not cover semaglutide (Wegovy) or tirzepatide (Zepbound) for weight loss either, reflecting a broader pattern among state Medicaid programs. As of early 2026, only 14 state Medicaid programs cover any GLP-1 receptor agonist specifically for obesity 6.

Montana Medicaid does cover GLP-1 receptor agonists for type 2 diabetes. If a Montana Medicaid enrollee has a concurrent diagnosis of type 2 diabetes and a provider prescribes retatrutide specifically for glycemic control (once FDA-approved for that indication), coverage through a prior authorization pathway may become possible. That remains speculative until Lilly receives approval and the state pharmacy and therapeutics committee reviews the drug.

Compounded Retatrutide in Montana: Legal and Available

Montana permits compounded retatrutide through 503A pharmacies. This is legal under both federal law (the Drug Quality and Security Act of 2013) and Montana's Board of Pharmacy regulations, provided the pharmacy holds a valid Montana license and compounds pursuant to a valid patient-specific prescription 7.

A 503A pharmacy compounds medications on an individual-patient basis after receiving a prescription. These pharmacies differ from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions. Both pathways exist in Montana, though most patients access compounded retatrutide through 503A pharmacies that ship to Montana addresses from licensed facilities in other states.

Pricing for compounded retatrutide in Montana varies significantly by pharmacy, dose, and supply chain. Typical quotes range from $200 to $500 per month for a once-weekly injection regimen, depending on the dose prescribed and the pharmacy's sourcing of active pharmaceutical ingredients. These prices sit well below the projected brand-name cost. The tradeoff: compounded products do not carry the same FDA oversight as commercially manufactured drugs, and potency, sterility, and stability testing varies by facility.

Montana patients considering compounded retatrutide should verify three things before ordering. First, confirm the pharmacy holds a current license with the Montana Board of Pharmacy or, if out-of-state, is registered to ship into Montana. Second, ask for a Certificate of Analysis (CoA) for the specific batch. Third, confirm the prescribing provider has evaluated the patient and determined that compounded retatrutide is clinically appropriate.

The FDA has placed certain GLP-1 receptor agonist peptides on its shortage list in recent years, which affects whether compounding pharmacies may legally produce them. Retatrutide's shortage status should be verified at the time of prescribing, as this directly determines whether 503A compounding is permitted under federal law 7.

Insurance Coverage for Retatrutide in Montana

No commercial insurance plan in Montana covers brand-name retatrutide in 2026 because the drug lacks FDA approval for commercial sale. Once Lilly receives approval, coverage decisions will depend on each plan's pharmacy and therapeutics committee review, formulary placement, and the approved indication.

Based on how Montana's major insurers handled tirzepatide and semaglutide, patients should anticipate the following pattern. Blue Cross Blue Shield of Montana, the state's largest commercial insurer, initially excluded Wegovy from its formulary when the drug launched in 2021. Coverage was added selectively in 2023 for patients meeting specific BMI and comorbidity criteria, with step therapy requiring prior failure on at least one other anti-obesity medication 8.

PacificSource Health Plans, which covers a significant portion of Montana's individual and small-group market, has historically required prior authorization for all GLP-1 receptor agonists prescribed for weight management. Allegiance Benefit Plan Management, a third-party administrator used by many Montana self-funded employer plans, leaves coverage decisions to each employer, creating wide variation across the state.

For Montana patients with employer-sponsored insurance, the key variable is whether the self-funded plan explicitly excludes anti-obesity medications. Many do. The Obesity Action Coalition estimates that approximately 40% of large-employer plans in the United States still carry explicit exclusions for weight-management drugs 9.

Patients should request a formulary exception or a letter of medical necessity from their prescribing provider. A strong letter should cite the patient's BMI, relevant comorbidities (type 2 diabetes, hypertension, obstructive sleep apnea, NAFLD/MASLD), prior failed interventions, and the Phase 2 data showing retatrutide's superior efficacy at 48 weeks 3.

How the Eli Lilly Savings Card May Work in Montana

Eli Lilly has not yet released a savings card specific to retatrutide, but the company's approach with tirzepatide provides a reliable template. When Mounjaro launched in 2022, Lilly offered a savings card that reduced the out-of-pocket cost to as low as $25 per month for commercially insured patients. The Zepbound savings program followed a similar structure 1.

Montana patients with commercial insurance (not Medicare, Medicaid, or Tricare) will likely be eligible for a manufacturer savings card once retatrutide reaches the market. These cards typically cover the difference between the patient's copay or coinsurance and a preset floor price, up to a maximum annual benefit.

Patients paying cash (no insurance) have historically been excluded from Lilly's copay card programs but may qualify for the Lilly Patient Assistance Program if their household income falls below 400% of the federal poverty level. For a single-person household in 2026, that threshold is approximately $62,400.

Montana residents in rural areas face an additional consideration: not every retail pharmacy accepts manufacturer copay cards. Specialty pharmacies and mail-order pharmacies tend to process these cards more reliably than independent rural pharmacies. Patients in towns like Miles City, Havre, or Glendive should confirm card acceptance before filling a prescription.

Telehealth Access to Retatrutide in Montana

Montana law permits telehealth prescribing of retatrutide statewide. The Montana Board of Medical Examiners allows providers to prescribe controlled and non-controlled substances via telehealth after establishing a valid provider-patient relationship through a real-time audio-video encounter 10.

Retatrutide is not a controlled substance. This simplifies telehealth prescribing because Montana does not require an in-person visit before initiating a non-controlled injectable medication. A provider licensed in Montana (or holding a valid interstate medical licensure compact credential) can evaluate a patient, order baseline labs, prescribe retatrutide, and arrange for medication delivery to any Montana address.

Several telehealth platforms already offer retatrutide consultations for Montana residents, primarily routing patients toward compounded formulations while the brand-name product remains unavailable. Consultation fees typically range from $99 to $199 for an initial visit, with follow-up visits priced between $49 and $99.

For Montana's rural population, telehealth represents a meaningful access point. Seventeen of Montana's 56 counties lack a single endocrinologist or obesity medicine specialist. Telehealth eliminates the 200-plus-mile round trips that patients in eastern Montana would otherwise need to reach obesity medicine clinics in Billings or Great Falls.

Strategies to Reduce Retatrutide Costs in Montana

Montana patients can pursue several concrete steps to minimize out-of-pocket spending on retatrutide as the drug moves toward commercial availability.

Check clinical trial eligibility. Eli Lilly's Phase 3 TRIUMPH program enrolled patients across multiple U.S. sites. Remaining open trials and extension studies may accept Montana residents. ClinicalTrials.gov lists active retatrutide studies with their inclusion criteria and site locations 3.

Compare 503A compounding quotes. Pricing varies by $100 to $300 per month across compounding pharmacies that ship to Montana. Request batch-specific Certificates of Analysis from at least two pharmacies before committing.

File a formulary exception early. If your commercial insurer excludes anti-obesity medications, submit a formulary exception with supporting clinical documentation before the first prescription fill. The appeals process in Montana typically takes 30 to 60 days for a standard review and 72 hours for an expedited review.

Explore health savings account (HSA) and flexible spending account (FSA) eligibility. Anti-obesity medications prescribed by a licensed provider for a diagnosed medical condition qualify as eligible HSA/FSA expenses under IRS guidelines. Montana residents with high-deductible health plans can use pre-tax dollars to offset retatrutide costs.

Monitor Montana legislative activity. Several states have introduced bills requiring commercial insurers to cover FDA-approved anti-obesity medications. Montana's 2025 legislative session did not pass such a bill, but the 2027 session may revisit the issue as triple-agonist data strengthens the clinical case for coverage mandates.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on obesity pharmacotherapy noted: "Access to effective anti-obesity pharmacotherapy should not be determined by geography or insurance status. Coverage parity with other chronic diseases remains a clinical and ethical priority" 5.